Alzamend Neuro, Inc.

The momentum for this stock is not very good. Alzamend Neuro, Inc. is not a good value stock. Alzamend Neuro, Inc. is not very popular among insiders. Alzamend Neuro, Inc. is a mediocre stock to choose.

News

Alzamend Neuro executed deal to provide sufficient capital for 18 months

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Alzamend Neuro Issues Letter to Stockholders

Business Wire Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...\n more…

Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher

Benzinga U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday. The Dow traded up 0.44% to 40,838.25 while the NASDAQ rose 0.18% to 17,663.86. The S&P 500 also rose, gaining, 0.27% to 5,569.39. Check This Out: Around $2M Bet On This Health Care Stock?\n more…

Alzamend Neuro teams with MGH for lithium drug AL001 trial to treat PTSD

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic

Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Large Increase in Short Interest

Ticker Report Alzamend Neuro, Inc. (NASDAQ:ALZN - Get Free Report) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totalling 17,200 shares, a growth...\n more…